Abstract
Background and Aims: Hypertensive patients often suffer from other metabolism related comorbidities characterized by insulin resistance (e.g., diabetes mellitus, metabolic syndrome). The pharmaceutical combination of telmisartan/amlodipine has been associated with beneficiary effects on glucose metabolism and insulin resistance. Dual combination treatment is advised with current guidelines. ARB and CCB combination are considered to have a beneficial affect on glucose homeostasis. We present comparative data of the effect of delapril/manidipine versus telmisartan/amlodipine combination treatments, in HOMA-IR, HOMA-B, HOMA-S and QUICKI indices before and after the 3-month treatment, in hypertensive prediabetic patients.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
